The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

That’s a drop in the ocean compared to the CHF 1.5 billion and CHF 910 million in Herceptin and Perjeta sales, respectively, in the same period, but with Phesgo Roche is looking to the future.

As a line extension, it expands the blockbuster drug franchise and extends the patent protection for Herceptin—a strategy Roche could apply to other biologics as well. “When we looked at the ...

However, Roche faced a CHF 1bn sales decline from the loss of exclusivity on older products, including cancer therapies Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan (rituximab).

Roche Holdings Ltd. (RHHBY) recently announced additional results from its phase III EMILIA study, which was conducted with trastuzumab emtansine. The study compared trastuzumab emtansine to ...

Roche Holdings Ltd. (RHHBY) reported positive data from a late-stage study (HannaH) on Herceptin (trastuzumab). According to the study, the new subcutaneous (SC) formulation of Herceptin showed ...

Blockbuster cancer biologics Avastin, Rituxan, and Herceptin are seeing strong headwinds from biosimilars. However, Roche's biologics focus (more than 80% of pharmaceutical sales) provides some ...

For the entire year, Phesgo increased (PDF) sales 62% to 1.74 billion Swiss francs (nearly $2 billion), Roche reported in late January. Herceptin sales fell 11% to 1.38 billion Swiss francs ($1.5 ...

Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. In a brief statement, the ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).